Brokerages Set Immunome, Inc. (NASDAQ:IMNM) Price Target at $23.33

Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have been assigned an average rating of "Buy" from the six analysts that are covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have issued a report on the stock in the last year is $23.33.

Several research firms have recently issued reports on IMNM. Wedbush restated an "outperform" rating and set a $21.00 price objective (down previously from $33.00) on shares of Immunome in a report on Tuesday, May 13th. Wall Street Zen upgraded Immunome from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Stephens reissued an "overweight" rating and issued a $30.00 price target on shares of Immunome in a research note on Thursday, March 20th. Guggenheim dropped their price objective on shares of Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, March 20th. Finally, Lake Street Capital assumed coverage on shares of Immunome in a report on Wednesday, April 2nd. They set a "buy" rating and a $23.00 price objective on the stock.

Insider Buying and Selling

In other news, Director Jean Jacques Bienaime acquired 5,000 shares of Immunome stock in a transaction dated Tuesday, June 3rd. The shares were acquired at an average cost of $9.38 per share, with a total value of $46,900.00. Following the purchase, the director now directly owns 36,415 shares of the company's stock, valued at approximately $341,572.70. This trade represents a 15.92% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Clay B. Siegall bought 137,100 shares of the firm's stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average price of $7.29 per share, with a total value of $999,459.00. Following the acquisition, the chief executive officer now directly owns 806,736 shares in the company, valued at approximately $5,881,105.44. This trade represents a 20.47% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 161,400 shares of company stock valued at $1,207,395. 8.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Voya Investment Management LLC grew its stake in Immunome by 21.2% during the first quarter. Voya Investment Management LLC now owns 18,905 shares of the company's stock worth $127,000 after buying an additional 3,305 shares during the period. Rhumbline Advisers raised its stake in shares of Immunome by 30.4% in the 1st quarter. Rhumbline Advisers now owns 88,888 shares of the company's stock valued at $598,000 after acquiring an additional 20,721 shares during the period. Woodline Partners LP lifted its holdings in shares of Immunome by 69.0% during the 1st quarter. Woodline Partners LP now owns 1,657,729 shares of the company's stock valued at $11,157,000 after acquiring an additional 676,804 shares in the last quarter. Zimmer Partners LP acquired a new position in shares of Immunome during the 1st quarter valued at $673,000. Finally, Exome Asset Management LLC purchased a new stake in Immunome during the 1st quarter worth $1,776,000. Hedge funds and other institutional investors own 44.58% of the company's stock.

Immunome Trading Down 1.3%

Shares of NASDAQ IMNM traded down $0.12 during midday trading on Thursday, reaching $8.83. 740,253 shares of the stock were exchanged, compared to its average volume of 917,910. The stock has a 50 day moving average price of $8.40 and a 200-day moving average price of $9.39. The company has a market capitalization of $768.32 million, a P/E ratio of -2.78 and a beta of 1.94. Immunome has a 52-week low of $5.15 and a 52-week high of $16.81.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.66) by $0.14. The firm had revenue of $2.93 million for the quarter, compared to analyst estimates of $0.46 million. Immunome had a negative net margin of 1,875.21% and a negative return on equity of 71.65%. On average, analysts forecast that Immunome will post -2.21 earnings per share for the current year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.